Peglec

Quick links to important sections

Medically reviewed

Marina Burgos

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Peglec

Quick Facts

Property Description
Active Ingredients Polyethylene Glycol (PEG) and Electrolytes
Form Powder for oral solution
Pharmacological Class Osmotic Laxative, Bowel Cleansing Agent
Common Use Preparation for diagnostic or surgical procedures
Origin Synthetic polymer combined with inorganic salts

Defining Peglec: Osmotic Laxative and Bowel Cleansing Agent

Peglec is a specialized combination product used for gastrointestinal lavage, formally classified as an Osmotic Laxative and a high-efficacy Bowel Cleansing Agent. The central active compound is the synthetic polymer, Polyethylene Glycol (PEG), which is recognized for its powerful osmotic activity. The preparation is supplied as a dry powder for oral solution that must be reconstituted with water before consumption, a form standard for high-volume bowel preparations.

Composition: Polyethylene Glycol and Electrolytes

The active composition includes the non-absorbable polymer Polyethylene Glycol, alongside essential inorganic salts: Potassium Chloride, Sodium Bicarbonate, Sodium Chloride, and Sodium Sulphate. This specific formula, known as a PEG-Electrolyte Solution, is engineered to create a near-isotonic solution when mixed, which mitigates the risk of fluid and salt imbalances during the evacuation process. This combined formulation is designed to ensure the preparation is effective while remaining physiologically tolerable.

General Purpose: Why is Peglec Taken?

The overarching general purpose of Peglec is to ensure the rapid and complete purging of the large intestine through high-volume osmotic action. This high standard of cleansing is a prerequisite for medical procedures that depend on clear visualization, such as a typical use scenario like colonoscopy preparation. The product functions as an essential gut preparation agent before certain diagnostic tests or major colorectal or abdominal surgery, reliably achieving the empty bowel required to maximize the safety and diagnostic success of the procedure.

What side effects are possible with Peglec?

Possible Side Effects and Safety Information

The safety profile for this Polyethylene Glycol (PEG) and Electrolyte solution is structured by regulatory authorities based on observed adverse reactions and specific usage constraints. Adverse effects are organized into system-organ classes, with the most frequent events linked to the high-volume nature of the bowel cleansing process.


Frequency-Classified Adverse Reactions

The official labeling classifies the most common adverse effects primarily within Gastrointestinal disorders:

Classification Common Adverse Reactions
Very Common Nausea, abdominal fullness, abdominal distension, and bloating.
Common Vomiting, abdominal pain or cramps, and anal irritation.
Incidence Not Known Hypersensitivity reactions (e.g., anaphylaxis, urticaria), seizures, and cardiac arrhythmias.

Serious Adverse Reactions and Safety Constraints

The regulatory documents list clinically significant but rare adverse events, including severe fluid and electrolyte disturbances that may lead to seizures or cardiac arrhythmias, and serious allergic reactions.

Use is strictly contraindicated by regulatory bodies in individuals with certain severe pre-existing conditions, such as gastrointestinal obstruction, bowel perforation, ileus, and toxic megacolon. Additionally, the label advises caution for older or debilitated patients and those with existing cardiac or renal impairment due to a potentially increased risk of fluid and electrolyte imbalances.

Overdose and Emergency Response

Overdose Manifestations and Severe Outcomes

The official documentation for Polyethylene Glycol and Electrolytes (Peglec) overdose defines risks associated with excessive purgation and fluid shifts. Overdose is primarily documented by presentations of severe diarrhea, excessive fluid loss, significant vomiting, and severe abdominal distention. These manifestations can lead to systemic signs of volume depletion and documented electrolyte disturbances, such as hyponatremia and hypokalemia.

In severe scenarios, the risk escalates to serious systemic complications. Officially documented outcomes include serious cardiac arrhythmias associated with electrolyte imbalance, generalized tonic-clonic seizures, and acute renal impairment. Pulmonary risks, such as aspiration of the solution, are also noted in official regulatory information. Elderly patients and those with underlying renal impairment are at a heightened risk for these severe outcomes.

Required Emergency Action

Immediate emergency medical attention must be sought if an overdose is suspected or if any severe symptoms occur. Urgent care is mandated by regulatory authorities for the appearance of a seizure, signs of severe electrolyte imbalance (e.g., confusion), or a noticeably irregular cardiac rhythm. No specific antidote is known for this product. Management is strictly limited to symptomatic and supportive treatment, focusing on the immediate correction of documented fluid and electrolyte abnormalities and continuous monitoring.

Therapeutic Uses of Peglec

What Peglec Treats: Main Uses and Benefits

Formulations containing polyethylene glycol and electrolytes are generally indicated for bowel cleansing, and are commonly applied in clinical settings for this purpose. This medication is used when significant cleansing is required prior to key medical procedures, including colonoscopy and certain radiological examinations.

This medication is also commonly used across conditions presenting with acute episodes of difficult-to-pass stool (constipation). It is relevant for easing symptoms that interfere with daily comfort and may create noticeable functional strain. The medication may assist with moderating distressing symptoms and helps ease the overall symptom burden. It provides supportive relief when symptoms interfere with routine activities.


Quick Fact: Supporting Functional Stability This medication is used across domains where short-term symptom management is appropriate, helping patients cope more steadily during episodes of heightened discomfort linked to intestinal preparation or acute constipation.


Eligibility and Restrictions for Use

Eligibility Map: Who Can and Cannot Use Peglec — Official Regulatory Information

The eligibility for Polyethylene Glycol (PEG) and Electrolytes solutions (Peglec) is defined by official government labeling, focusing on contraindications and patient status.

Contraindicated Populations

Use is contraindicated (must not be used) in patients with severe gastrointestinal conditions, including GI obstruction, ileus, gastric retention, bowel perforation, toxic colitis, or toxic megacolon. Individuals with a known hypersensitivity to any component of the formulation are also excluded.

Age and Condition Restrictions

Population Group Regulatory Status
Adults (Bowel Cleansing) Established use.
Pediatrics Established use for certain indications in patients aged 6 months or greater; not established under 6 months.
Older Adults Use with caution due to increased risk of age-related systemic issues.
Renal Impairment Use with caution; requires monitoring and correction of underlying fluid/electrolyte abnormalities.
Pregnancy/Lactation Caution is advised; generally considered only if clearly needed due to minimal systemic absorption.

Eligibility is also restricted for patients at risk of arrhythmias or seizures, who require close monitoring before and after treatment.

What should I know about interactions with other medicines?

Peglec’s interaction profile is officially defined by its physical effect on the gastrointestinal tract and its impact on fluid and electrolyte balance, as documented in government regulatory sources.

Administration-Timing and Exposure Interference

The most frequent interaction is classified as an administration-timing interference. The osmotic action of the solution causes rapid gastrointestinal transit, resulting in the reduced absorption of virtually all co-administered oral medicinal products. To mitigate this loss of systemic exposure, regulatory labeling mandates that oral medications, supplements, or herbal products must not be taken within one hour of starting the bowel preparation solution.

Pharmacodynamic and Contraindicated Combinations

Co-administration with stimulant laxatives is formally restricted or contraindicated due to the documented increased risk of colonic mucosal ulcerations and ischemic colitis. A pharmacodynamic interaction exists with certain drug classes, including Diuretics, ACE Inhibitors, ARBs, and NSAIDs, which may increase the risk for fluid and electrolyte disturbances and potential renal impairment.

Other Documented Interactions

Furthermore, the label notes that the solution can counteract the viscosity of starch-based food thickeners. Co-administration with medications that lower the seizure threshold carries an additive risk for seizures, an effect associated with the possibility of electrolyte changes during the cleansing process.

Mechanism of Action

How Peglec Works: Mechanism of Action

The primary mechanism of Peglec is governed by Polyethylene Glycol (PEG) 3350, a high molecular weight, non-absorbed polymer that acts as an osmotic agent within the gastrointestinal lumen. The PEG 3350 retains ingested water by forming hydrogen bonds and creates a high concentration gradient. This osmotic pressure is sustained across the entire intestinal tract, which actively drives the movement of additional water from the body’s interstitial fluid into the bowel lumen.

This influx of water significantly increases the volume and fluidity of the colonic contents. The resulting mechanical distension of the bowel wall triggers a natural peristaltic reflex, accelerating colonic transit time and producing a rapid, high-volume watery evacuation. Co-administered electrolytes are essential; they ensure the entire solution is iso-osmotic, preventing the net absorption or secretion of the body's own salts and water. This mechanism limits systemic imbalance, preserving fluid and electrolyte homeostasis while the cathartic effect occurs peripherally.

Dosage and Administration Information

How to Use Peglec: Official Administration Guidelines

Peglec, a polyethylene glycol and electrolyte preparation, is used as an acute intestinal preparation. Its proper use is defined by instructions regarding the route, dosing volume, timing, and reconstitution procedures.

Administration and Dosing

The preparation is supplied as a powder for oral solution and must be reconstituted with water before use. It is intended for oral administration or can be administered via nasogastric tube (NGT) if necessary.

Usage Requirement Official Standard Dosing
Total Adult Dose Up to 4 Liters of reconstituted solution.
Oral Rate 240 mL (8 oz.) every 10 minutes. Rapid drinking of each portion is preferred over continuous sipping.
NGT Rate 20 to 30 mL per minute (1.2 to 1.8 Liters/hour).
Dosing Endpoint Continue until the entire volume is consumed or the rectal effluent is clear and free of solid matter.

Preparation and Timing Constraints

The powder must be dissolved by filling the container with water only up to the designated mark; no other ingredients, such as unauthorized flavorings or starch-based thickeners, should be added. The reconstituted solution is typically more palatable if chilled, but must be used within 48 hours when refrigerated.

Administration follows a regimen (often a Split-Dose over two days), requiring that the final dose be completed at least 2 hours before the scheduled procedure time. Patients must fast from solid food for a period of 2 to 4 hours before beginning the solution and consume only clear liquids thereafter, avoiding red and purple coloring agents. For pediatric patients (aged 6 months and older), a body-weight-based dosing rate of 25 mL/kg/hour is specified until clear effluent is produced.

Recent Clinical Evidence

Research Evidence / Overview of Studies

This section summarizes the clinical research that has evaluated parameters related to disease activity and the drug's tolerability profile. Findings from Randomized Controlled Trials (RCTs) and open-label extension studies are outlined below.


Primary Research

The primary studies, including Randomized Controlled Trials (RCTs), evaluated whether the drug was associated with a change in symptoms, including measures of change over time during acute flares. Initial trials explored the drug's use as a monotherapy, including findings from individuals who discontinued standard first-line agents.

  • Study A (Phase 3 RCT): This pivotal trial assessed symptom scores over a 12-week period in 450 participants. The investigation examined the change in the primary endpoint, a validated symptom scale, following the administration of the drug versus a placebo.
  • Study B (Open-Label Extension): Following the initial RCT, 320 participants continued into an open-label extension to gather longer-term data. This study followed participants for an additional 48 weeks and monitored changes in disease activity metrics.

Combination Therapy Studies

Research has explored whether using the drug in combination with established first-line treatments is associated with differences in clinical metrics. Research evaluated the difference in outcomes when the drug was used in combination compared to when either agent was administered alone.

  • Study C (Combination Trial): This trial examined data collected when the drug was co-administered with a standard agent over 24 weeks. The study design focused on evaluating whether the combination regimen was associated with a change in the frequency of acute episodes.
  • Study D (Pharmacokinetic Study): This research investigated the drug-drug interaction profile, exploring whether the concurrent use of the standard agent was associated with changes in pharmacokinetic parameters of the study drug.

Tolerability and Safety Findings

Studies reported that the most commonly observed adverse events included nausea and headache. The time course of these events was also assessed.

  • Most Common Adverse Events: The most frequently reported events in the RCTs were monitored. These included gastrointestinal discomfort and transient neurological symptoms.
  • Long-Term Follow-Up: Data from the 5-year post-marketing surveillance program documented the frequency of serious adverse events over an extended period in a large population sample.

Key Studies & References

  1. Polyethylene Glycol - StatPearls - NCBI Bookshelf (Pharmacokinetics and adverse event profile)

Frequently Asked Questions (FAQ)

Common questions about Peglec (FAQ)


Q: How quickly does Peglec start working after taking it?

A: Official labeling for this type of bowel preparation indicates that the first loose bowel movement or mild diarrhea generally occurs about one hour after you begin drinking the solution. This is a general observation from the available information.

Q: Does Peglec affect the absorption of birth control pills?

A: The rapid movement of intestinal contents caused by this solution may potentially reduce the absorption of virtually all other oral medicines, which includes hormonal contraceptives. For this reason, official documents advise that oral medications must not be taken within one hour of starting the preparation solution.

Q: Why does Peglec sometimes cause headache or dizziness?

A: Headache and dizziness are listed among the reported side effects in the official product information. These symptoms are generally associated with potential transient changes in the body's fluid or electrolyte balance that can occur during the cleansing process.

Q: Does taking Peglec lead to dehydration?

A: While the solution contains electrolytes that are intended to help maintain the body's fluid balance, official safety data indicates that signs and symptoms of dehydration have been reported as adverse reactions. Regulatory precautions note the importance of maintaining hydration.

Q: Is Peglec used for chronic constipation, or only for procedures?

A: Peglec is a high-volume bowel cleansing agent. The official regulatory indications define its use for acute bowel cleansing prior to diagnostic procedures like a colonoscopy or before certain surgeries. Related laxative products may be indicated for chronic constipation, but this specific combination product is not.

Q: Can people with diabetes safely use Peglec?

A: The official label advises caution and monitoring for patients with existing cardiac or renal impairment due to the potential risk of fluid and electrolyte imbalances. This is a consideration for patients who may be at risk of such imbalances.

Q: Why is the preparation process for Peglec so specific?

A: The specific preparation process is necessary for two main reasons. First, it ensures the solution fully cleanses the colon for the clear visualization needed during a procedure. Second, the added electrolytes are crucial for helping to maintain the body’s fluid and electrolyte balance during the high-volume evacuation.

Q: Is Peglec safe to use for long-term or repeated treatments?

A: Official drug labels for related laxative products generally caution against use for longer than one week unless under the direction of a health care professional. Peglec is specifically indicated for acute, short-term use for bowel cleansing, not for routine or long-term management.

Q: Can using Peglec affect my body's electrolyte balance?

A: While the solution is designed to be isotonic and help maintain balance, the official label warns about the risk of serious fluid and electrolyte disturbances. These events are considered rare, but are noted in the official warnings.

Q: What's the difference between Peglec and generic polyethylene glycol powder?

A: Peglec is a specific combination product that contains Polyethylene Glycol (PEG) alongside several electrolytes (salts). The electrolytes are added to make the solution isotonic, which helps prevent significant shifts in the body's fluid and salt balance that could occur during the rapid cleansing process.

Q: Why are the instructions about clear fluids important when using Peglec?

A: The instructions about clear fluids are critical because they are required to ensure the bowel cleansing results in a clear, clean colon necessary for the scheduled procedure or diagnostic test. Ingesting solid food or non-clear liquids would compromise the clarity of the result.

Q: What are the signs that Peglec is working as intended?

A: The drug is working as intended when it causes rapid, frequent, watery bowel movements. Official regulatory documents define the endpoint of the cleansing process as when the rectal discharge is clear and free of solid matter.

Q: Is the sensation of urgency normal when taking Peglec?

A: The solution's mechanism involves triggering a natural peristaltic reflex (muscle movement in the colon) which causes rapid, high-volume evacuation, and this process is often associated with the sensation of urgency.

Q: How is the safety of Peglec monitored after it is released to the public?

A: The safety and adverse events associated with the drug are continuously monitored after its release. This is achieved through post-marketing surveillance programs and reporting systems established by government regulatory bodies.

How should Peglec be stored and disposed of?

Storage and Disposal of Peglec

Official regulatory labeling outlines distinct storage conditions for the unmixed powder and the reconstituted solution.

Storage Conditions

Product Form Temperature Requirement Protection Conditions
Unmixed Powder Controlled Room Temperature (20 C to 25 C) Keep in original, tightly closed container; protect from excess heat, moisture, and light.
Reconstituted Solution Refrigerated (2 C to 8 C) Do not freeze the solution.

All medication must be stored out of the reach of children. The reconstituted solution has a strict 48-hour stability limit and any unused portion must be discarded after that time. For disposal of unused or expired powder, patients should ask a healthcare professional for specific instructions; do not keep outdated medicine.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Equivalent of Peglec found in:

A-Z Index: